Please wait while we load the requested 10-Q report or click the link below:
https://last10k.com/sec-filings/report/1505497/000149315223016630/form10-q.htm
SEC Filings
BRTX Annual Reports
BRTX Quarterly Reports
BRTX Corporate News
Financial Exhibit
Regulated Disclosure March 2024
Financial Exhibit
New Agreement
Other Events
Unregistered Sales February 2024
Financial Exhibit
Regulated Disclosure February 2024
Financial Exhibit
Regulated Disclosure February 2024
Vote of Security Holders September 2023
Financial Exhibit
New Agreement
Other Events July 2023
Financial Exhibit
New Agreement April 2023
Financial Exhibit
Other Events April 2023
Financial Exhibit
Security Holders Change January 2023
Vote of Security Holders November 2022
Financial Exhibit
Regulated Disclosure
Regulated Disclosure
March 2024
Financial Exhibit
New Agreement
Other Events
Unregistered Sales
New Agreement
Other Events
Unregistered Sales
February 2024
Financial Exhibit
Regulated Disclosure
Regulated Disclosure
February 2024
Financial Exhibit
Regulated Disclosure
Regulated Disclosure
February 2024
Vote of Security Holders
September 2023
Financial Exhibit
New Agreement
Other Events
New Agreement
Other Events
July 2023
Financial Exhibit
New Agreement
New Agreement
April 2023
Financial Exhibit
Other Events
Other Events
April 2023
Financial Exhibit
Security Holders Change
Security Holders Change
January 2023
Vote of Security Holders
November 2022
BRTX Registration of Securities
Last10K.com | 10-Q Quarterly Report Fri May 12 2023
Cover - shares | 3 Months Ended | |
|---|---|---|
Mar. 31, 2023 | May 12, 2023 | |
| Cover [Abstract] | ||
| Document Type | 10-Q | |
| Amendment Flag | false | |
| Document Quarterly Report | true | |
| Document Transition Report | false | |
| Document Period End Date | Mar. 31, 2023 | |
| Document Fiscal Period Focus | Q1 | |
| Document Fiscal Year Focus | 2023 | |
| Current Fiscal Year End Date | --12-31 | |
| Entity File Number | 001-37603 | |
| Entity Registrant Name | BIORESTORATIVETHERAPIES, INC. | |
| Entity Central Index Key | 0001505497 | |
| Entity Tax Identification Number | 30-1341024 | |
| Entity Incorporation, State or Country Code | NV | |
| Entity Address, Address Line One | 40 Marcus Drive | |
| Entity Address, City or Town | Melville | |
| Entity Address, State or Province | NY | |
| Entity Address, Postal Zip Code | 11747 | |
| City Area Code | (631) | |
| Local Phone Number | 760-8100 | |
| Title of 12(b) Security | Common Stock, $0.0001 par value | |
| Trading Symbol | BRTX | |
| Security Exchange Name | NASDAQ | |
| Entity Current Reporting Status | Yes | |
| Entity Interactive Data Current | Yes | |
| Entity Filer Category | Non-accelerated Filer | |
| Entity Small Business | true | |
| Entity Emerging Growth Company | false | |
| Entity Shell Company | false | |
| Entity Bankruptcy Proceedings, Reporting Current | true | |
| Entity Common Stock, Shares Outstanding | 3,887,615 |
View differences made from one quarter to another to evaluate Biorestorative Therapies, Inc.'s financial trajectory
Compare this 10-Q Quarterly Report to its predecessor by reading our highlights to see what text and tables were removed , added and changed by Biorestorative Therapies, Inc..
Assess how Biorestorative Therapies, Inc.'s management team is paid from their Annual Proxy
Biorestorative Therapies, Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2023 10-K Annual Report includes:
- Voting Procedures
- Board Members
- Executive Team
- Salaries, Bonuses, Perks
- Peers / Competitors
SEC Filing Tools
Rating
Learn More
Filter Sentiment:
Filter Category:
Filter Subcategory:
-
Revenue - Product Highlight
20 Net cash provided by investing activities increased by $2,618,205 for the three months ended March 31, 2023 compared to the three months ended March 31, 2022, primarily due to a sale of marketable securities, which provided $2,568,654 of cash.
-
Financial - Expense Highlight
We expect that our general and administrative expenses will increase as we expand our staff, develop our infrastructure and incur additional costs to support the growth of our business.
-
Other - Other Highlight
Gain on PPP loan forgiveness During the three months ended March 31, 2022, our outstanding PPP loan balance was forgiven in full, which was recorded as a gain in the condensed consolidated statement of operations.
-
Other - Other Highlight
These statements are only predictions and involve known and unknown risks, uncertainties and other factors, including the risks set forth in the section entitled "Risk Factors" in our Annual Report on Form 10-K for the fiscal year ended December 31, 2022, as filed with the U.S. Securities and Exchange Commission (the "SEC") on March 27, 2023, any of which may cause our company's or our industry's actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied in our forward-looking statements.
-
Financial - Expense
Net cash used in operating...Read more
-
Revenue - Product
Effects of Inflation We do...Read more
-
Other - Other
Pursuant to the license agreement,...Read more
-
Financial - Expense
We expect that our higher...Read more
-
Other - Other
We may be unable to...Read more
-
Financial - Expense
For the three months ended...Read more
-
Legal - Other
We undertake no obligation to...Read more
-
Other - Other
However, based on cash on...Read more
Financial Statements, Disclosures and Schedules
Inside this 10-Q Quarterly Report
Cover
Condensed Consolidated Balance Sheets
Condensed Consolidated Balance Sheets (Parenthetical)
Condensed Consolidated Statements Of Cash Flows (Unaudited)
Condensed Consolidated Statements Of Changes In Stockholders' Equity (Unaudited)
Condensed Consolidated Statements Of Operations (Unaudited)
Accrued Expenses And Other Current Liabilities
Accrued Expenses And Other Current Liabilities (Tables)
Basis Of Presentation And Summary Of Significant Accounting Policies
Basis Of Presentation And Summary Of Significant Accounting Policies (Details Narrative)
Basis Of Presentation And Summary Of Significant Accounting Policies (Policies)
Basis Of Presentation And Summary Of Significant Accounting Policies (Tables)
Intangible Assets
Intangible Assets (Details Narrative)
Intangible Assets (Tables)
Leases
Leases (Details Narrative)
Leases (Tables)
Nature Of The Organization, Liquidity, And Business
Nature Of The Organization, Liquidity, And Business (Details Narrative)
Schedule Of Accrued Expenses And Other Current Liabilities (Details)
Schedule Of Fair Value Recurring Basis (Details)
Schedule Of Future Minimum Payments Under Non-Cancelable Leases For Operating Leases (Details)
Schedule Of Intangible Assets (Details)
Schedule Of Intangible Assets Amortization Expenses (Details)
Schedule Of Net Lease Cost And Other Supplemental Lease Information (Details)
Schedule Of Stock Compensation By Award Type (Details)
Schedule Of Stock Option Activity (Details)
Schedule Of Stock Option Expense (Details)
Schedule Of Stock Options Granted Assumptions (Details)
Schedule Of Unvested Restricted Stock Units (Details)
Schedule Of Weighted Average Dilutive Common Shares (Details)
Stockholders??? Equity
Stockholders??? Equity (Details Narrative)
Stockholders??? Equity (Tables)
Subsequent Events
Subsequent Events (Details Narrative)
Material Contracts, Statements, Certifications & more
Biorestorative Therapies, Inc. provided additional information to their SEC Filing as exhibits
Ticker: BRTX
CIK: 1505497
Form Type: 10-Q Quarterly Report
Accession Number: 0001493152-23-016630
Submitted to the SEC: Fri May 12 2023 4:05:39 PM EST
Accepted by the SEC: Fri May 12 2023
Period: Friday, March 31, 2023
Industry: Health And Allied
External Resources:
Stock Quote
Social Media
SEC.gov
Bookmark the Permalink: https://last10k.com/sec-filings/brtx/0001493152-23-016630.htm
SEC Filing Exhibit
PDF Download
Loading SEC Filing Exhibit...
Excel DownloadLoading SEC Filing Financial Summary...